Cytokinetics (CYTK) Convertible Debt (2019 - 2026)

Cytokinetics (CYTK) has reported Convertible Debt for 7 consecutive years, with $889.5 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Convertible Debt rose 61.3% year-over-year to $889.5 million; the TTM figure through Sep 2025 stood at $889.5 million (up 61.3% YoY), while the FY2024 annual figure was $552.4 million, up 0.62% from the prior year.
• Convertible Debt advanced to $889.5 million in Q3 2025 per CYTK's latest filing, from $554.0 million in the prior quarter.
• Across five years, Convertible Debt topped out at $889.5 million in Q3 2025 and bottomed at $90.9 million in Q1 2021.
• Historically, Convertible Debt has averaged $427.6 million across 5 years, with a median of $547.3 million in 2023.
• Annual changes were most pronounced in 2022 — Convertible Debt surged 480.48% — and 2023, when it advanced 0.58%.
• Cytokinetics' Convertible Debt stood at $95.5 million in 2021, then jumped by 471.7% to $545.8 million in 2022, then grew by 0.58% to $549.0 million in 2023, then climbed by 0.62% to $552.4 million in 2024, then soared by 61.04% to $889.5 million in 2025.
• Business Quant data shows CYTK's Convertible Debt at $889.5 million in Q3 2025, $554.0 million in Q2 2025, and $553.1 million in Q1 2025.